Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Supernus Pharmaceuticals Inc. (SUPN) Insider Trading Activity
Healthcare • Drug Manufacturers - Specialty & Generic • 652 employees
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.
Total Value
-$9,763,901.78
Total Shares
89,876
Average Trade Value
-$137,519.74
Most Active Insider
Khattar Jack A.
Total Activity: $12,321,792
Largest Single Transaction
$4,585,000
by Khattar Jack A. on Nov 7, 2024
30-Day Activity
12 Transactions
Volume: 8,038 shares
Value: $265,656
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Svp, Chief Medical Officer
Officer
|
Mar 5, 2025 | 314 | $10,378 | 10,789 (-2.9%) | Payment of Exercise Price | |
|
Svp, Quality, Gmp, Ops, It
Officer
|
Mar 5, 2025 | 945 | $31,232 | 13,882 (-6.8%) | Payment of Exercise Price | |
|
Senior Vice-president CFO
Officer
|
Mar 5, 2025 | 1,587 | $52,450 | 12,228 (-13.0%) | Payment of Exercise Price | |
|
Senior Vice-president CFO
Officer
|
Mar 5, 2025 | 1,330 | $43,957 | 10,898 (-12.2%) | Payment of Exercise Price | |
|
Sr. VP of Ip, Cso
Officer
|
Mar 5, 2025 | 575 | $19,004 | 12,704 (-4.5%) | Payment of Exercise Price | |
|
Sr. VP of Ip, Cso
Officer
|
Mar 5, 2025 | 575 | $19,004 | 13,279 (-4.3%) | Payment of Exercise Price | |
|
Sr. VP of Ip, Cso
Officer
|
Mar 5, 2025 | 335 | $11,072 | 13,854 (-2.4%) | Payment of Exercise Price | |
|
Senior Vice-president CFO
Officer
|
Mar 5, 2025 | 276 | $9,122 | 13,815 (-2.0%) | Payment of Exercise Price | |
|
Svp, Chief Medical Officer
Officer
|
Mar 5, 2025 | 577 | $19,070 | 9,635 (-6.0%) | Payment of Exercise Price | |
|
Svp, Chief Medical Officer
Officer
|
Mar 5, 2025 | 577 | $19,070 | 10,212 (-5.7%) | Payment of Exercise Price | |
|
Svp, Quality, Gmp, Ops, It
Officer
|
Mar 5, 2025 | 337 | $11,138 | 15,437 (-2.2%) | Payment of Exercise Price | |
|
Svp, Quality, Gmp, Ops, It
Officer
|
Mar 5, 2025 | 610 | $20,161 | 14,827 (-4.1%) | Payment of Exercise Price | |
|
Svp, Quality, Gmp, Ops, It
Officer
|
Feb 26, 2025 | 3,750 | $10,000 | 17,683 (+21.2%) | Exercise/Conversion | |
|
Svp, Quality, Gmp, Ops, It
Officer
|
Feb 26, 2025 | 2,010 | $10,000 | 14,909 (+13.5%) | Exercise/Conversion | |
|
Svp, Quality, Gmp, Ops, It
Officer
|
Feb 26, 2025 | 976 | $38,532 | 13,933 (-7.0%) | Payment of Exercise Price | |
|
Svp, Quality, Gmp, Ops, It
Officer
|
Feb 26, 2025 | 1,909 | $75,367 | 15,774 (-12.1%) | Payment of Exercise Price | |
|
Senior Vice-president CFO
Officer
|
Feb 23, 2025 | 2,500 | $10,000 | 14,091 (+17.7%) | Grant | |
|
Svp, Chief Medical Officer
Officer
|
Feb 23, 2025 | 1,250 | $10,000 | 11,103 (+11.3%) | Grant | |
|
Svp, Quality, Gmp, Ops, It
Officer
|
Feb 23, 2025 | 1,875 | $10,000 | 12,899 (+14.5%) | Grant | |
|
Sr. VP of Ip, Cso
Officer
|
Feb 23, 2025 | 1,250 | $10,000 | 14,189 (+8.8%) | Grant | |
|
Director
|
Feb 22, 2025 | 5,369 | $10,000 | 53,764 (+10.0%) | Grant | |
|
Svp, Quality, Gmp, Ops, It
Officer
|
Feb 22, 2025 | 1,250 | $10,000 | 11,024 (+11.3%) | Grant | |
|
Svp, Quality, Gmp, Ops, It
Officer
|
Feb 22, 2025 | 750 | $10,000 | 9,774 (+7.7%) | Grant | |
|
Svp, Chief Medical Officer
Officer
|
Feb 22, 2025 | 750 | $10,000 | 8,603 (+8.7%) | Grant | |
|
Svp, Chief Medical Officer
Officer
|
Feb 22, 2025 | 1,250 | $10,000 | 9,853 (+12.7%) | Grant | |
|
Sr. VP of Ip, Cso
Officer
|
Feb 22, 2025 | 1,250 | $10,000 | 12,939 (+9.7%) | Grant | |
|
Sr. VP of Ip, Cso
Officer
|
Feb 22, 2025 | 750 | $10,000 | 11,689 (+6.4%) | Grant | |
|
Director
|
Feb 22, 2025 | 5,369 | $10,000 | 5,369 (+100.0%) | Grant | |
|
Director
|
Feb 22, 2025 | 5,369 | $10,000 | 22,570 (+23.8%) | Grant | |
|
Senior Vice-president CFO
Officer
|
Feb 22, 2025 | 500 | $10,000 | 8,591 (+5.8%) | Grant | |
|
Senior Vice-president CFO
Officer
|
Feb 22, 2025 | 3,000 | $10,000 | 11,591 (+25.9%) | Grant | |
|
Director
|
Feb 22, 2025 | 5,369 | $10,000 | 135,644 (+4.0%) | Grant | |
|
Director
|
Feb 22, 2025 | 5,369 | $10,000 | 18,684 (+28.7%) | Grant | |
|
Sr. VP of Ip, Cso
Officer
|
Feb 21, 2025 | 1,650 | $10,000 | 11,799 (+14.0%) | Exercise/Conversion | |
|
Sr. VP of Ip, Cso
Officer
|
Feb 21, 2025 | 860 | $33,669 | 10,939 (-7.9%) | Payment of Exercise Price | |
|
Svp, Chief Medical Officer
Officer
|
Feb 21, 2025 | 927 | $36,292 | 7,853 (-11.8%) | Sale | |
|
Svp, Chief Medical Officer
Officer
|
Feb 21, 2025 | 1,875 | $10,000 | 8,780 (+21.4%) | Exercise/Conversion | |
|
Svp, Quality, Gmp, Ops, It
Officer
|
Feb 21, 2025 | 552 | $21,611 | 9,024 (-6.1%) | Payment of Exercise Price | |
|
Svp, Quality, Gmp, Ops, It
Officer
|
Feb 21, 2025 | 1,125 | $10,000 | 9,576 (+11.7%) | Exercise/Conversion | |
|
Sr. VP of Ip, Cso
Officer
|
Feb 4, 2025 | 9,477 | $376,237 | 10,149 (-93.4%) | Sale | |
|
Sr. VP of Ip, Cso
Officer
|
Feb 4, 2025 | 9,477 | $280,614 | 19,626 (+48.3%) | Exercise/Conversion | |
|
Sr. VP of Ip, Cso
Officer
|
Jan 28, 2025 | 700 | $27,734 | 10,149 (-6.9%) | Sale | |
|
Sr. VP of Ip, Cso
Officer
|
Jan 28, 2025 | 700 | $20,727 | 10,849 (+6.5%) | Exercise/Conversion | |
|
Sr. VP of Ip, Cso
Officer
|
Jan 27, 2025 | 2,573 | $101,942 | 10,149 (-25.4%) | Sale | |
|
Sr. VP of Ip, Cso
Officer
|
Jan 27, 2025 | 2,573 | $76,187 | 12,722 (+20.2%) | Exercise/Conversion | |
|
Director
|
Jan 22, 2025 | 20,000 | $182,600 | 48,395 (+41.3%) | Exercise/Conversion | |
|
Svp, Chief Medical Officer
Officer
|
Dec 27, 2024 | 281 | $10,001 | 5,541 (-5.1%) | Payment of Exercise Price | |
|
President, CEO
Director, Officer
|
Dec 27, 2024 | 38,640 | $10,000 | 964,812 (+4.0%) | Exercise/Conversion | |
|
Svp, Chief Medical Officer
Officer
|
Dec 27, 2024 | 1,875 | $10,000 | 7,416 (+25.3%) | Exercise/Conversion | |
|
Svp, Chief Medical Officer
Officer
|
Dec 27, 2024 | 821 | $29,219 | 6,595 (-12.4%) | Payment of Exercise Price | |
|
Svp, Chief Medical Officer
Officer
|
Dec 27, 2024 | 750 | $0 | 5,822 (+12.9%) | Exercise/Conversion | |
|
President, CEO
Director, Officer
|
Dec 27, 2024 | 14,000 | $10,000 | 960,245 (+1.5%) | Exercise/Conversion | |
|
President, CEO
Director, Officer
|
Dec 27, 2024 | 6,666 | $237,243 | 953,579 (-0.7%) | Payment of Exercise Price | |
|
President, CEO
Director, Officer
|
Dec 27, 2024 | 18,567 | $660,800 | 946,245 (-2.0%) | Payment of Exercise Price | |
|
Sr. VP of Ip, Cso
Officer
|
Dec 3, 2024 | 8,750 | $209,913 | 18,429 (+47.5%) | Exercise/Conversion | |
|
Sr. VP of Ip, Cso
Officer
|
Dec 3, 2024 | 8,750 | $320,950 | 9,679 (-90.4%) | Sale | |
|
Sr. VP of Ip, Cso
Officer
|
Dec 3, 2024 | 12,745 | $322,449 | 22,424 (+56.8%) | Exercise/Conversion | |
|
Sr. VP of Ip, Cso
Officer
|
Dec 3, 2024 | 12,745 | $467,487 | 9,679 (-131.7%) | Sale | |
|
Director
|
Nov 11, 2024 | 20,000 | $182,600 | 140,975 (+14.2%) | Exercise/Conversion | |
|
Director
|
Nov 11, 2024 | 10,700 | $387,768 | 130,275 (-8.2%) | Sale | |
|
Director
|
Nov 8, 2024 | 10,787 | $391,568 | 13,315 (-81.0%) | Sale | |
|
President, CEO
Director, Officer
|
Nov 8, 2024 | 125,000 | $4,536,250 | 926,172 (-13.5%) | Sale | |
|
President, CEO
Director, Officer
|
Nov 8, 2024 | 125,000 | $1,141,250 | 1,051,172 (+11.9%) | Exercise/Conversion | |
|
Director
|
Nov 8, 2024 | 8,722 | $316,434 | 28,395 (-30.7%) | Sale | |
|
Director
|
Nov 8, 2024 | 10,787 | $123,619 | 24,102 (+44.8%) | Exercise/Conversion | |
|
President, CEO
Director, Officer
|
Nov 7, 2024 | 125,000 | $1,141,250 | 1,051,172 (+11.9%) | Exercise/Conversion | |
|
President, CEO
Director, Officer
|
Nov 7, 2024 | 125,000 | $4,585,000 | 926,172 (-13.5%) | Sale | |
|
Svp, Quality, Gmp, Ops, It
Officer
|
Nov 7, 2024 | 15,000 | $136,950 | 23,200 (+64.7%) | Exercise/Conversion | |
|
Director
|
Nov 7, 2024 | 14,213 | $520,480 | 13,315 (-106.7%) | Sale | |
|
Svp, Quality, Gmp, Ops, It
Officer
|
Nov 7, 2024 | 15,000 | $554,700 | 8,200 (-182.9%) | Sale | |
|
Director
|
Nov 7, 2024 | 14,213 | $162,881 | 27,528 (+51.6%) | Exercise/Conversion |